. Disruption of miRNA regulation may affect ccRCC immunogenicity and response to ICI therapy, making them

in the expression of miRNAs) and designing their targeted therapy using specific miRNAs as targets. This article

Герминальные мутации как возможные биомаркеры эффективности терапии ингибиторами контрольных точек иммунитета у пациентов с почечно-клеточной карциномой (мини-обзор)Germline mutations as possible biomarkers of immune checkpoint inhibitor therapy efficacy

cancellation and therapy failure. Modern studies demonstrate evidence that exosomes are of great importance

researched – 89.91%, despite a good response to primary therapy, had a relapse of the disease after 7 years

and for targeted therapy of age-associated pathologies, including malignant neoplasms. In this regard, the study

–60% of differences in sensitivity to therapy in patients with BA is due to genetic variability. We studied